The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Targeting the transferrin receptor for brain drug delivery
Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …
development of therapeutics to treat diseases of the central nervous system. The main …
[HTML][HTML] Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles
Rationale: The ability to treat invalidating neurological diseases is impeded by the presence
of the blood-brain barrier (BBB), which inhibits the transport of most blood-borne substances …
of the blood-brain barrier (BBB), which inhibits the transport of most blood-borne substances …
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives
OM Alzghool, G van Dongen… - Movement …, 2022 - Wiley Online Library
ABSTRACT α‐Synucleinopathies including idiopathic Parkinson's disease, dementia with
Lewy bodies and multiple systems atrophy share overlapping symptoms and pathological …
Lewy bodies and multiple systems atrophy share overlapping symptoms and pathological …
Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
Abstract Background Transferrin receptor (TfR1) mediated enhanced brain delivery of
antibodies have been studied extensively in preclinical settings. However, the brain …
antibodies have been studied extensively in preclinical settings. However, the brain …
[HTML][HTML] In vivo imaging of alpha-synuclein with antibody-based PET
S Roshanbin, M Xiong, G Hultqvist, L Söderberg… - …, 2022 - Elsevier
The protein alpha-synuclein (αSYN) plays a central role in synucleinopathies such as
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …
Engineered antibodies: new possibilities for brain PET?
Almost 50 million people worldwide are affected by Alzheimer's disease (AD), the most
common neurodegenerative disorder. Development of disease-modifying therapies would …
common neurodegenerative disorder. Development of disease-modifying therapies would …
[HTML][HTML] Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography
Focused ultrasound (FUS) is a minimally-invasive technology used for treatment of many
diseases, including diseases related to the colon, uterus, prostate, and brain. Although it has …
diseases, including diseases related to the colon, uterus, prostate, and brain. Although it has …
Molecular tools to detect alloforms of Aβ and Tau: Implications for multiplexing and multimodal diagnosis of Alzheimer's disease
The advancements in the field of imaging and diagnostics have been benefitted by the
concurrent expansion of molecular probes space to monitor the diverse biological targets …
concurrent expansion of molecular probes space to monitor the diverse biological targets …
Pretargeted imaging beyond the blood–brain barrier
V Shalgunov, SL van den Broek, IV Andersen… - RSC medicinal …, 2023 - pubs.rsc.org
Pretargeting is a powerful nuclear imaging strategy to achieve enhanced imaging contrast
for nanomedicines and reduce the radiation burden to healthy tissue. Pretargeting is based …
for nanomedicines and reduce the radiation burden to healthy tissue. Pretargeting is based …